Literature DB >> 2006182

Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells.

B N Cronstein1, M A Eberle, H E Gruber, R I Levin.   

Abstract

Although commonly used to control a variety of inflammatory diseases, the mechanism of action of a low dose of methotrexate remains a mystery. Methotrexate accumulates intracellularly where it may interfere with purine metabolism. Therefore, we determined whether a 48-hr pretreatment with methotrexate affected adenosine release from [14C]adenine-labeled human fibroblasts and umbilical vein endothelial cells. Methotrexate significantly increased adenosine release by fibroblasts from 4 +/- 1% to 31 +/- 6% of total purine released (EC50, 1 nM) and by endothelial cells from 24 +/- 4% to 42 +/- 7%. Methotrexate-enhanced adenosine release from fibroblasts was further increased to 51 +/- 4% (EC50, 6 nM) and from endothelial cells was increased to 58 +/- 5% of total purine released by exposure to stimulated (fMet-Leu-Phe at 0.1 microM) neutrophils. The effect of methotrexate on adenosine release was not due to cytotoxicity since cells treated with maximal concentrations of methotrexate took up [14C]adenine and released 14C-labeled purine (a measure of cell injury) in a manner identical to control cells. Methotrexate treatment of fibroblasts dramatically inhibited adherence to fibroblasts by both unstimulated neutrophils (IC50, 9 nM) and stimulated neutrophils (IC50, 13 nM). Methotrexate treatment inhibited neutrophil adherence by enhancing adenosine release from fibroblasts since digestion of extracellular adenosine by added adenosine deaminase completely abrogated the effect of methotrexate on neutrophil adherence without, itself, affecting adherence. One hypothesis that explains the effect of methotrexate on adenosine release is that, by inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase, methotrexate induces the accumulation of AICAR, the nucleoside precursor of which (5-aminoimidazole-4-carboxamide ribonucleoside referred to hereafter as acadesine) has previously been shown to cause adenosine release from ischemic cardiac tissue. We found that acadesine also promotes adenosine release from and inhibits neutrophil adherence to connective tissue cells. The observation that the antiinflammatory actions of methotrexate are due to the capacity of methotrexate to induce adenosine release may form the basis for the development of an additional class of antiinflammatory drugs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2006182      PMCID: PMC51248          DOI: 10.1073/pnas.88.6.2441

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Adenosine receptors on human lymphocytes.

Authors:  G Marone; S Vigorita; M Triggiani; M Condorelli
Journal:  Adv Exp Med Biol       Date:  1986       Impact factor: 2.622

2.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

3.  Engagement of adenosine receptors inhibits hydrogen peroxide (H2O2-) release by activated human neutrophils.

Authors:  B N Cronstein; S M Kubersky; G Weissmann; R Hirschhorn
Journal:  Clin Immunol Immunopathol       Date:  1987-01

4.  The effects of adenosine agonists on human neutrophil function.

Authors:  D J Schrier; K M Imre
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

5.  Regulation of macrophage lysosomal secretion by adenosine, adenosine phosphate esters, and related structural analogues of adenosine.

Authors:  D W Riches; J L Watkins; P M Henson; D R Stanworth
Journal:  J Leukoc Biol       Date:  1985-05       Impact factor: 4.962

6.  Adenosine; a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils.

Authors:  B N Cronstein; E D Rosenstein; S B Kramer; G Weissmann; R Hirschhorn
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

7.  Synergistic action of adenosine and fMet-Leu-Phe in raising cAMP content of purified human monocytes.

Authors:  K R Elliott; P J Miller; H C Stevenson; E J Leonard
Journal:  Biochem Biophys Res Commun       Date:  1986-08-14       Impact factor: 3.575

8.  Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells.

Authors:  B N Cronstein; R I Levin; J Belanoff; G Weissmann; R Hirschhorn
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

9.  Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates.

Authors:  C J Allegra; J C Drake; J Jolivet; B A Chabner
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

10.  Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide.

Authors:  J E Baggott; W H Vaughn; B B Hudson
Journal:  Biochem J       Date:  1986-05-15       Impact factor: 3.857

View more
  74 in total

Review 1.  Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors:  N Fathy; D E Furst
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis.

Authors:  M Cutolo; A Sulli; C Pizzorni; B Seriolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2001-08       Impact factor: 19.103

Review 3.  Molecular mechanism of methotrexate action in inflammation.

Authors:  B N Cronstein
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

Review 4.  Suppression of inflammatory and immune responses by the A(2A) adenosine receptor: an introduction.

Authors:  T M Palmer; M A Trevethick
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

5.  Going with the flow: methotrexate, adenosine, and blood flow.

Authors:  B N Cronstein
Journal:  Ann Rheum Dis       Date:  2006-04       Impact factor: 19.103

6.  Low-dose methotrexate results in the selective accumulation of aminoimidazole carboxamide ribotide in an erythroblastoid cell line.

Authors:  Ryan S Funk; Leon van Haandel; Mara L Becker; J Steven Leeder
Journal:  J Pharmacol Exp Ther       Date:  2013-07-25       Impact factor: 4.030

Review 7.  The Role of Adenosine Receptor Activation in Attenuating Cartilaginous Inflammation.

Authors:  Jonathan M Bekisz; Christopher D Lopez; Carmen Corciulo; Aranzazu Mediero; Paulo G Coelho; Lukasz Witek; Roberto L Flores; Bruce N Cronstein
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

Review 8.  Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Ben A C Dijkmans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils.

Authors:  B N Cronstein; Y Molad; J Reibman; E Balakhane; R I Levin; G Weissmann
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

10.  [Methotrexate in rheumatology].

Authors:  C Fiehn
Journal:  Z Rheumatol       Date:  2009-11       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.